Malkani Dhiraj H 4

What Happened
Dhiraj H. Malkani, Chief Strategy Officer of Kiniksa Pharmaceuticals International, received multiple equity awards on July 1, 2026. The filing reports six derivative awards (grants) totaling 103,459 units: 82,600; 14,000; 2,119; 2,188; 1,245; and 1,307. Each was reported at an acquisition price of $0.00 (i.e., awarded as compensation rather than purchased). These awards include a mix of stock-settled units and performance/option awards subject to vesting and performance conditions.

Key Details

• Transaction date: July 1, 2026; Form 4 filed July 6, 2026 (appears to be filed after the 2-business-day Form 4 deadline).
• Reported awards (all "A" = grant/acquisition at $0.00): 82,600; 14,000; 2,119; 2,188; 1,245; 1,307 — total 103,459 derivative units. Total reported cash paid = $0.00.
• Shares/units owned after transaction: Not specified in the filing.
• Notable footnotes (summary):
  • F1: An option vests 25% after one year from vesting commencement (July 1, 2026), then monthly over 36 months.
  • F2–F3: RSUs (each convertible to one Class A share) vest over four years with 25% vesting each year starting July 1, 2026.
  • F4: One award is subject to an earnout (0–100%); the filing reflects 100% achievement.
  • F5–F6: Performance Share Options (PSOs) vest upon FDA BLA submission (F5) or upon FDA approval for commercial sale (F6), subject to continued employment.
  • F7–F9: Performance Share Units (PSUs) convert to Class A shares upon satisfaction of performance milestones tied to FDA submission (F8) or approval (F9).
• Filing timeliness: The Form 4 was filed July 6, 2026 for a July 1 transaction; this appears to miss the typical 2-business-day deadline and may be considered late.

Context
These were grants/awards (derivative instruments and contingent share units), not open-market purchases or sales. RSUs/PSUs represent contingent rights to receive shares upon vesting and/or achievement of specified milestones; PSOs are options that vest only if specified regulatory milestones for KPL-387 (recurrent pericarditis) are met. Because these are compensation awards with vesting and performance conditions, they reflect company compensation decisions rather than an executive buying or selling shares for personal investment.